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 Introduction 
 There is a now a growing international consensus that development of 
the pharmaceutical industry in Africa can contribute to both economic 
development and improved public health. This final chapter begins by 
identifying the striking convergence of thought and initiative that has 
recently been generated across continental African representative bodies, 
international agencies and national governments. We outline this emer-
gent consensus and then examine challenges it faces by focusing on the 
core interconnected policy issues of financing and incentives for indus-
trial development in pharmaceuticals. A sustainable and expanding 
pharmaceutical industry must reach essential quality standards and also 
constantly upgrade, moving up the technology ladder while improving 
cost efficiency. This requires a cocktail of incentives in which finance 
is key (Chataway et al., 2009). These incentives, in turn, rely on the 
building up of appropriate financial capabilities within firms and finan-
cial institutions as well as within governments. This chapter innovatively 
traces the interconnections between micro-level financial capabilities 
and national government policy competences in the design and effec-
tive implementation of financial incentives and associated policies to 
facilitate industrial development in pharmaceuticals in Africa. 
 The emerging commitment: transforming pharmaceutical 
manufacturing in Africa 
 At the African continental level, the African Union Commission (AUC) 
identified the imperative of pharmaceutical industry development in 
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their  Pharmaceutical Manufacturing Plan for Africa (PMPA) (AU, 2007), 
endorsed at the African Union Heads of State and Government Summit 
in 2007. Progress on realizing the ambition espoused in this document 
was initially slow to materialize, prompting the Conference of African 
Ministers of Health (CAMH) to call at their fifth meeting in 2011 for 
a ‘Business Plan’ for the accelerated implementation of the PMPA. A 
partnership was formed later that year between the AUC and the United 
Nations Industrial Development Organization (UNIDO) to develop the 
business plan, and in May 2012 the resulting document (AU, 2012a) was 
approved by a special session of the CAMH in Geneva. In July 2012 the 
Business Plan was endorsed by AU Heads of State and Government at 
their summit in Addis Ababa. 
 Regionally and institutionally, collaborative work on local pharma-
ceutical development has snowballed. The African Ministers of Industry 
have also now recognized the pharmaceutical industry as a priority, in 
the Accelerated Industrial Development of Africa (AIDA) framework 
endorsed at their 19th meeting in Algiers in 2011. African Regional 
Economic Communities have also developed plans. The East African 
Community Regional Pharmaceutical Manufacturing Plan of Action 
2012–16 was launched in 2011 (EACRPMPA, 2011). The West African 
Health Organization (WAHO) has been developing the Economic 
Community of West African States (ECOWAS)  Regional Pharmaceutical 
Plan (ERPP) and its implementation. The ERPP explicitly aligns with the 
principles and objectives of the Business Plan for the PMPA, and WAHO 
has rapidly developed a comprehensive approach, despite wrestling with 
the unprecedented crisis of the Ebola outbreak in the region. 
 The public health commitment 
 International organizations concerned with public health are also now 
indicating growing support for this agenda. The Joint United Nations 
Programme on HIV/AIDS (UNAIDS) under the leadership of Michel 
Sidibé has long been an advocate of the importance of strengthening 
local production, in particular to address the sustainability of HIV/AIDS 
treatment, as well as access to medicines for tuberculosis and malaria. 
It is a central component of Pillar Two of the African Union’s  Shared 
Responsibility and Global Solidarity Roadmap for HIV, TB and Malaria 
Response in Africa , developed with support from UNAIDS (AU, 2012b). 
 In 2008 the World Health Assembly adopted the  Global Plan of Action 
and Strategy on Public Health , a broad document that identifies the role that 
local production of essential medicines could play in improving public 
health. As part of its implementation, the World Health Organization 
280 West and Banda
(WHO) has run an EU Commission-funded project to assess this role. 
Phase 1 of the study concludes that the development of the local phar-
maceutical industry does not inevitably lead to improved public health, 
and hence that promoting the public health impact should be central 
to efforts to strengthen the industry. These initiatives have helped to 
ensure that public health considerations are central to the Business 
Plans that are being developed. They plot a practical path whereby the 
industry can contribute to both public health and economic develop-
ment agendas that were previously considered by some to be mutually 
exclusive (Kaplan and Laing, 2005). 
 The strong current consensus amongst the international community, 
that the development of the pharmaceutical sector in Africa is an imper-
ative, was notably underlined by the Joint WHO Bulletin Editorial by 
Mr Sidibé, Mr Li (Director General of UNIDO) and Dr Chan (Director 
General of WHO) (Sidibé et al., 2014). The authors strongly supported 
the development of the industry in Africa through the implementation 
of the PMPA Business Plan. 
 The challenge of implementation 
 Practical bilateral and multilateral support for the industry is growing. 
The German government has a long track record of supporting the 
pharmaceutical industry in Africa. Since 2006 it has funded a UNIDO 
project on strengthening the local production of essential medicines 
in developing and least-developed countries, a project initiated by the 
previous UNIDO Director General Dr Kandeh Yumkella. Bilaterally 
through its aid agency Deutsche Gesellschaft für Internationale 
Zusammenarbeit (GIZ), Germany has supported the EAC pharmaceu-
tical plan and many other initiatives such the bioequivalence centre in 
Addis Ababa (see Chapter 5) and initial feasibility studies for a similar 
centre in Ghana. 
 Other international support includes the United States Pharmacopeial 
Convention (USP) which, with funding from the United States Agency 
for International Development (USAID), has been running a programme 
on Promoting the Quality of Medicines (PQM), including capacity 
building for manufacturers and regulators. In 2013 it opened the Centre 
for Advanced Pharmaceutical Training (CePAT) in Ghana, to train regu-
lators and the industry in quality assurance and quality control. The 
St. Lukes Foundation in Tanzania has similarly been training industry 
professionals on international standards of production through its 
Industrial Pharmacy Advanced Training Programme, taught by US 
academics from Purdue and Howard universities, supported by UNIDO. 
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The need to exploit opportunities under the exemptions and flexibili-
ties offered by the Trade Related Aspects of Intellectual Property Rights 
(TRIPS)  agreement 1 has led the United Nations Development Programme 
(UNDP), the United Nations Conference on Trade and Development 
(UNCTAD) and the African Regional Intellectual Property Organization 
(ARIPO), amongst others, to establish relevant programmes. 
 The PMPA  Business Plan identifies the problem of a piecemeal 
approach that has not delivered rapid development of the industry, 
and proposes that coordination across different initiatives is required. 
The international organizations need to invest in supporting emerging 
national and regional processes to enable development of the industry. 
Coordinated technical assistance is required to support relatively weak 
skills availability in the short term and to engage in capacity develop-
ment across public and private sectors for the long-term sustainability of 
the industry. National governments too need to invest to support their 
industries: this point was underscored during a high-level side event 
at the Ministers of Finance and Economic Planning meeting co-hosted 
by the African Union Commission and the United Nations Economic 
Commission for Africa (UNECA) in Abuja in March 2014. 
 Ghana is an example of a country where a coordinated agenda is 
progressing. In October 2013 early implementation of the AUC’s PMPA 
 Business Plan began in Ghana, following an invitation from President 
Mahama to the Chairperson of the AUC, Dr Nkosazana Dlamini Zuma. 
A technical assistance work plan was agreed by the national stakeholders 
and a consortium of partners including UNIDO, WHO, UNAIDS, UNDP, 
UNFPA, the New Partnership for Africa’s Development (NEPAD), the 
African Network for Drug and Diagnostic Innovation (ANDI) and the 
Federation of African Pharmaceutical Manufacturer’s Associations 
(FAPMA). The work plan recognizes both the critical need to build 
capacity within public sector institutions and the private sector and the 
need within the industry for time and support to invest in upgrading. 
 The need for complex cross-institution coordination to implement the 
work plan is illustrated by the collaboration with the Ghanaian Food and 
Drug Authority (FDA) to develop and implement a good manufacturing 
practices (GMP) road map; the development of training modules for 
industry on developing capital investment plans and managing capital 
project life cycles; the creation of a business linkages platform to enable 
companies to access the know-how that they require in the short term 
whilst internal technical capacity is developed; and a market data initia-
tive to provide market transparency to inform policy makers, industry 
and investors in their decision making. Technical assistance has also 
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been provided to assist government in assessing investment proposals 
made by pharmaceutical companies under the Export Development 
and Agriculture Investment Fund (EDAIF) stimulus package, described 
below. 
 Upgrading, market consolidation and the challenge 
of finance 
 Central to all this work is the recognition that the pharmaceutical sector 
in Africa needs to upgrade standards in order to be able to provide safe, 
efficacious, quality-assured essential medicines. Achieving this objec-
tive is a highly complex undertaking requiring coordinated action of 
many parties at national, regional, continental and international levels 
(Chapter 12). Africa-based companies are able to compete at interna-
tional standards, contrary to some earlier expressed views (see Chapter 6; 
Chaudhuri and West, 2014). The most technically advanced compa-
nies such as Universal in Kenya (WHO-prequalified for its Lamivudine 
Zidovudine FDC), Quality Chemicals International Limited in Uganda 
(with additional site licence for Cipla’s pre-qualified products) and four 
companies in Nigeria that have recently received WHO-GMP certifica-
tion (including May and Baker and Evans Pharmaceuticals) have attained 
high international standards. 
 However, the industry’s contribution to economic development and 
improved public health requires a broader swathe of companies to 
upgrade to international quality standards, not just for products to treat 
the major pandemics but for all medicines that have a critical role to play 
in treating communicable and non-communicable diseases. As earlier 
chapters have shown, companies across Africa are striving to upgrade 
their facilities and their manufacturing processes and procedures. 
However, whilst there have been no published systematic studies on 
the range of quality standards to which manufacturers on the continent 
adhere, it is clear that many companies licensed to manufacture phar-
maceuticals in Africa currently operate in premises and/or have quality 
management systems that fall below what should be acceptable. 
 The concept of the GMP ‘road map’ establishes rising quality targets 
over a defined period of time. During transition to meet these milestones, 
those companies that are operating below them should be restricted to 
manufacturing products where the risk to health is minimized. Such a 
stepwise approach creates a transition process for the industry whilst 
protecting public health. So long as the requirements are enforced by 
credible sanctions, the framework can discourage unproductive use of 
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subsidies by manufacturers not in practice investing in upgrading. It 
also provides some market protection for leading companies that have 
made significant investment, since they can sell a broader range of prod-
ucts during the transition phase. 
 The PMPA Business Plan focuses initially on generic small-molecule 
non-sterile production of final formulations in Africa. Even with this 
subset of essential medicines, the complexity of the system within which 
manufacturing takes place is significant (see Chapter 2). The industry has 
multiple stakeholders, operates in widely varying contexts across coun-
tries and regions, and includes manufacturers at significantly different 
levels of industrial development. 
 Nevertheless, some general requirements for industry development 
can be identified, and of these the central requirement is finance. 
Companies need to access capital to invest in retrofitting facilities or 
building new plants to meet international standards. The magnitude 
of investment required will depend on many variables including the 
specific pharmaceutical forms that a manufacturer wishes to produce, 
the scale of the plant and the starting point of the organization, but most 
companies will require at least US$10 million (see also Chapter 5 for the 
financial requirements for a start-up). The efficient use of this invest-
ment requires that companies in this knowledge-intensive industry can 
access the capabilities to design and build GMP-compliant plants and 
develop or acquire the capabilities to run them. Companies need assist-
ance to access know-how, time to develop plans and implement them, 
and more time to develop the capabilities first to operate efficiently and 
then to adapt and innovate. 
 Upgrading is done by companies, not governments. But policy makers 
and international development organizations need to understand the 
challenges faced by manufacturers, and to work with them and with 
national and regional entities to enable effective upgrading whilst 
avoiding wasteful use of scarce resources. The AUC has recognized 
this need for close collaboration, convening a consortium of conti-
nental and international partners, including the Federation of African 
Pharmaceutical Manufacturers Associations (FAPMA), to implement the 
PMPA Business Plan. The consortium will work with African trade asso-
ciations, regions and sovereign states on strategies for upgrading the 
industry. 
 Regulatory market shaping 
 In order to invest sustainably, pharmaceutical companies also need 
access to a large and effectively regulated market in which returns can be 
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made. Further strengthening of regulatory authorities is needed to ensure 
that legitimate manufacturers do not face competition from spurious, 
substandard and counterfeit products. Pharmaceutical manufacturers 
also need to utilize capacity efficiently in order to be competitive, and 
market scale is an important contributor to achieving cost efficiency. 
Since many African countries’ populations are relatively small, current 
efforts to defragment African regional markets, and confidence in their 
likely success, are vital prerequisites to mobilizing investment for many 
pharmaceutical manufacturers. While for a few firms international 
donor-funded markets may offer larger-scale market opportunities, the 
sustainability of an exclusive focus on these markets in the long term is 
questionable. 
 Important progress has been made in the direction of regional market 
consolidation, through the African Medicines Regulatory Harmonization 
initiative (AMRH), particularly in the EAC and ECOWAS Regional 
Economic Communities. The documentation for regulatory approval 
across member states will at least be standardized, removing significant 
transaction costs from manufacturers, and boding well for increasingly 
harmonized regulatory requirements in the future (see Chapter 12). 
 Finally, as earlier chapters have documented, local manufacturers are 
frequently at an inherent disadvantage in competition with imported 
medicines, and corrections to the tax and tariff frameworks are required 
at regional level. The ECOWAS Regional Pharmaceutical Plan (ERPP) 
advocates for zero tariffs on raw materials, machinery and equipment 
for pharmaceutical manufacturing within the Regional Economic 
Community and exemption of inputs from VAT. It also recognizes the 
need for an appropriate regional framework to support the stepwise 
approach to upgrading. 
 Such initiatives can help investors to assess potential returns. However, 
the quantification of the market opportunities remains elusive, given 
the paucity of market data for most African countries and regions. This 
market opacity increases the perceived risk for investors, leading in turn 
to higher interest payments through an increased risk coupon required 
for debt providers, or to a higher internal rate of return required by 
equity investors. The cost of investment capital for African pharmaceu-
tical investors remains a barrier for many companies in countries where 
interest rates on bank loans may exceed 25%. The next two sections 
tackle the funding challenge in more detail, first from the point of view 
of the manufacturers and private financing institutions, and then from 
the point of view of governments seeking to enable investment for 
industrial growth. 
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 Building financial capabilities in manufacturers and 
financial institutions 
 The African local pharmaceutical industry is playing technological 
catch-up based on building technological capabilities (Chapter 2). 
These technological capabilities are sometimes summarized as know-
what, know-how, know-why and know-who (Ernst and Lundvall, 1997). 
They include the skills needed for investment, production and creating 
market and non-market linkages (Lall, 1992): using technology effec-
tively for expansion; handling key production systems from quality 
control and operation and maintenance to adaptation and improve-
ment; and dealing effectively with suppliers and customers. While it is 
accepted that finance plays a strategic role in funding working capital 
requirements and capital investment, it is however less well documented 
that many Africa-based firms lack essential capabilities in raising and 
managing finance effectively (Banda, 2013). 
 The essential finance capabilities include the ability to understand 
a project life cycle and phase finance and to structure the most rele-
vant type of financial product. It also encompasses lending technology, 
pricing and an overall financial approach that does not choke the finan-
cial health of the borrowing firm, but rather enhances its productive 
capacity. Financial capability involves knowing where to get the most 
appropriately structured financial products, from whom, and when to 
use them. These firm-level financial capabilities are particularly impor-
tant for developing-country contexts, where financial systems are not 
well developed and growth of capital-intensive enterprises depends on 
capital investment financing (long-term foreign loans), in most cases 
from offshore sources. 
 In this section we explore finance capability in the firm and finan-
cial institution. This discussion is grounded in empirical work carried 
out on Zimbabwean pharmaceutical companies and financial institu-
tions, and additional interviews with pharmaceutical sector players in 
Uganda, Kenya, Tanzania and Ethiopia up to 2013. We analyse how 
firms use finance expertise and competencies, to identify and manage 
short-, medium- and long-term funding cycles. We focus on financial 
institutions at a micro-level and attempt to tease out the technical 
knowledge and capabilities needed to competently assess, classify, 
monitor and manage risks. The classes of risk may include credit, 
management, performance, regulatory, foreign exchange, payment 
and market risk which in various combinations manifest during a 
project lifecycle. 
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 The financing context for pharmaceutical firms in Africa 
 Economic, social and financial history shows sources of finance for 
setting up enterprises globally have been predominantly internal or 
own finance, made up of savings, wealth and loans from family and 
friends (Lazonick and O’Sullivan, 1997a, 1997b), in the industrialization 
era. Enterprise growth was funded internally by retained earnings, and 
externally banks were the most prevalent source of finance historically 
(Lazonick and O’Sullivan, 1997a, 1997b), specifically for the period from 
1970 to 1989 (Corbett and Jenkinson, 1996). Other sources of external 
finance were venture capitalists and capital markets. The key determi-
nants of financing source were the enterprise’s management experience, 
skills and credit reputation. 
 Growing companies with experienced management, poor to good 
future prospects, medium to high risk and established credit reputa-
tions are likely to use banks as sources of external funds (Corbett and 
Jenkinson, 1996). African enterprise financing studies similarly find that 
of all external funding sources, bank finance has been the most preva-
lent (Fafchamps et al., 1995.) 
 For established companies, with established credit records, low credit 
risk and run by experienced management, capital markets are the most 
likely source of external finance. However, capital markets did not play 
a major role in raising capital for industrialization, except to a certain 
extent in the US (Lazonick and O’Sullivan, 1997a, 1997b). Capital 
markets were used particularly to transfer ownership of corporate entities 
from family-run or close-knit ownership structures to publicly quoted 
companies, rather than to raise finance for industrialization. 
 Capital markets, however, are of little significance in Sub-Saharan 
African markets because of their small scale and low capitalization, with 
the possible exceptions of South Africa, Nigeria and Kenya. Venture 
capital and capital markets are more the exception than the norm in 
Africa. A more important source of external finance is foreign direct 
investment (FDI), which can embody technology flows (Portelli and 
Narula, 2004). FDI allows the developing country to import tech-
nology without payment, since the investor brings in knowledge and 
skills required to operate the technology. Ensuring effective technology 
transfer is a challenge. However, data on financing manufacturing 
industry in seven countries in Sub-Saharan Africa indicate that FDI 
and external/offshore financing were the main sources of capital, rein-
forcing Ndlela’s (2007) and Riddell’s (1990) accounts of FDI as being 
critical for the emergence of the manufacturing industry in countries 
such as Zimbabwe. 
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 How then do firms select internal or external avenues for financing 
investment? Internal funds include retained earnings, depreciation 
or fresh equity injection from existing shareholders. External funds 
include bank debt, hybrid bonds or issuing of new equity to new share-
holders. When internal funds are limited, management seeks external 
funds. A ‘pecking order’ theory (Myers, 1984) argues that in the face 
of limited information, firms will prefer to use own financial resources 
such as retained earnings or profits; only if self-financing is insufficient 
will management use external debt instruments: first bank debt, then 
hybrid bonds, and the last option will be new equity. The order of pref-
erence is determined by the objective of retaining management control. 
Hybrid securities such as convertible bonds dilute management control 
less, and carry fewer external accountability (discipline and reporting) 
requirements compared to stock exchange equity. Equity is a last resort 
because of onerous reporting standards and controls when dealing with 
broad shareholding structures and professional managers as agents of 
shareholders (Myers and Majluf, 1984). 
 Finance capability gaps in pharmaceutical firms 
 Faced with these financing constraints and choices, a firm with limited 
internal funds needs to develop capabilities to scan for potential funders 
and financial products nationally, regionally and internationally. The 
firm needs to articulate its organizational, dynamic and technological 
capabilities in a robust well-argued project finance document with 
supporting data. In building the project finance document and data, 
the firm needs to use its external networks to assess economic, industry 
and business environments and attendant risks, as well as stress-testing 
project data. The finance department as the key operating contact point 
with external financiers articulates the firm’s competencies and capabili-
ties in procurement (trade credit included), research and development, 
production and engineering, as well as sales and marketing capabilities. 
Table 15.1 Column 1 summarizes the financial capabilities the firms 
require. 
 The firm then needs to negotiate with financial institutions on appro-
priate finance products by competently structuring the debt or equity 
relevant to business needs. If this is not managed properly, financial insti-
tutions can push their preferred high-yielding products. The firm may 
then be burdened with finance products characterized by high charges, 
onerous covenants, triggers and security (collateral) requirements. Firms 
thus have a great deal to gain from finance capability to identify and 
structure appropriate borrowing products and negotiate on pricing. 
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Our interview data show, however, that these finance capabilities are 
lacking in many firms. One respondent in Zimbabwe remarked that the 
firms ‘were afraid to approach international banks because they are not 
able to produce a robust project proposal and are afraid of being asked 
questions’. Crafting a project proposal requires knowledge of the firms’ 
 Table 15.1  Finance capabilities at the firm and financial institution levels 
 Pharmaceutical firms’ required 
competencies 
 Funder’s (financial institutions’) 
required competencies 
 Identify the businesses’ financial needs:
Working capital and capital investment 
requirements 
Understand the industry, business, 
economic, political, and regulatory 
environment.
Ascertain the best available financing 
structure; a mix of short, medium and 
long term finance through debt, equity 
or hybrid instruments to structure the 
funding model for the firm
Sector-specific knowledge to 
competently identify, analyse 
and manage risks in business, 
industry, management, markets 
and regulation. Some funders have 
a central set of industry and sector 
specific skills that assists all business 
units.
Structuring the funding model requires 
development of knowledge of lending 
technologies and funding instruments 
on the market and outside national 
borders
Alignment of internal capabilities 
in prospecting, screening, analysis, 
structuring financial products/
funding schemes, document 
perfection, disbursement of funds, 
monitoring and control and eventual 
repayment of principal and interest.
Crafting a competent project finance 
proposal that identifies project risks 
and how they are managed through 
the management, organisational and 
technological capabilities of the firm.
Whilst managing projects identify 
opportunities and the exhibit 
flexibility to change within and after 
the life of the funded project.
Competency to apply financial resources 
to originally identified funding needs, 
and through financial management 
capability run successive asset 
conversion cycles to generate profit and 
maintain commercial viability.
Through learning-by-doing transfer 
skills and capabilities developed to 
other industrial sectors and within 
departments in the institution.
Competence to repay interest and 
principal on time, and meet challenges 
in restructuring debt after negotiation 
with the funders.
 Source : Compiled by author from fieldwork in Zimbabwe, 2010–13. 
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capabilities, what the money is needed for, and how revenue will be 
generated to repay debt. Based on the dynamics of the proposed project 
business cycles, the firm needs to be able to know which financing tool 
would be most advantageous to it instead of waiting for the bank to 
always propose the mode of financing. 
 Building finance capabilities in banks 
 Finance capability in financial institutions refers to their ability to source 
projects to invest in (investment capability); analyse the risks; structure 
the finance instrument, price the debt instrument and loan duration; 
followed by monitoring and control and eventually repayment of the 
debt by the borrower. Various players within the financial institution 
interact in the process of financing a project. The internal staff identify 
and analyse risks that include but are not limited to business, industry, 
management, country, political and foreign currency risks. The risk 
management process is closely tied to loan structuring, documentation, 
disbursement and monitoring and control procedures. 
 These processes depend on in-depth knowledge of the sector being 
assessed (Table 15.1). In practice, information is opaque and hard to 
assess. Our research evidence from Zimbabwe and secondary data 
evidence from East and West Africa suggests lack of in-depth and relevant 
pharmaceutical sector knowledge by financial institutions. A repeated 
claim by pharmaceutical executives is that financial institutions do not 
understand the business of African pharmaceutical drug manufacture. 
Evidence from Zimbabwe suggests that financiers also need to develop 
an in-depth knowledge of the economy, industry and health sector for 
preliminary analysis of projects. They need to greatly improve their 
networking within the financial sector and the national economy to 
acquire relevant information for prospecting and analysing projects. 
 Table 15.2 maps, using Lall’s (1992) concept of firm-level technolo-
gies, the capabilities needed by these financial institutions. The table 
maps prospecting, risk analysis, facility structuring and documenta-
tion, loan approval, loan disbursement, monitoring and control and 
ultimately loan repayment. Under prospecting capabilities, relationship 
managers use investment and networking capabilities to scout different 
industrial sectors for potential deals. They need intimate knowledge 
of the economy, industry, various business sectors, credit policy and 
underwriting standards. Interview respondents pointed to the use of 
both codified and tacit knowledge at this early stage. They empha-
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networks evidencing the need for linkage capabilities. Risk analysis, loan 
structuring and approval use codified and tacit knowledge for decision 
making by way of agreed financial ratios and internal metrics. Chief 
Risk Officers also acknowledged the inherent use of ‘gut feel’, implying 
relevance of tacit knowledge. 
 Capabilities that need to be built thus include loan disbursement, 
monitoring and control and finally repayment of the loan (Table 15.2). 
The process involves agreement of terms and conditions between the 
borrower and financier through a loan agreement document (commonly 
called the loan facility). On fulfilment of the conditions precedent, the 
loan administration department processes the security for the loan 
facility and disburses the funds. Monitoring and control is based on 
the conditions set out in the loan facility. The capabilities at this stage 
include those of product and process engineering and also linkage capa-
bilities. Our evidence from empirical work in Zimbabwe and interviews 
with pharmaceutical executives from East Africa shows a clear perception 
of financial institutions’ deficit of in-depth knowledge of pharmaceu-
tical manufacturing business dynamics and attendant risks and oppor-
tunities. These challenges were acknowledged by financial institution 
executives who agreed that they did not understand the pharmaceutical 
industry. This information asymmetry and opacity leads to classification 
of the African pharmaceutical manufacturing sector as high-risk, nega-
tively influencing loan pricing. 
 The financiers and pharmaceutical executives interviewed proposed 
to tackle these failings through training and exposure to the pharma-
ceutical industry. Finance capability cannot be taken for granted and 
requires purposive and strategic investment to build these competences. 
An illustration of what can be done is drawn from an innovative mid-
career recruitment programme of one international bank in Zimbabwe; 
Standard Chartered Bank. This programme allowed the bank to build 
skills and a broader knowledge base by recruiting non-traditional bank 
trained professionals (Table 15.3). This formed part of an Africa-wide 
initiative by Standard Chartered Bank Africa. 
 A senior manager who has since left the bank said this programme 
was a short-term strategic move to fill an identified skills gap. This 
seems paradoxical; an innovative and strategic approach which could 
have contributed a longer term strategy to generate risk analysis skills 
for project management and build capabilities was relegated to a short 
term measure. The senior manager argued that once the identified skills 
gap had been filled, they could revert to the usual graduate trainee 
programme and train in-house. He argued that the mid-career entrants 
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came in at middle-management level, were more expensive to the bank 
and so reverting to the cheaper junior level graduate trainees helped 
contain costs. However it is clear that these ‘non-traditional bankers’ 
had added value to credit risk analysis, management and monitoring, 
with their specialist skills and in-depth technical knowledge. They 
served as a knowledge bank that junior and senior management tapped 
into to understand once-opaque industrial operations. As Table 15.3 
shows, many of these recruits’ skills were used to build a deeper tech-
nical knowledge of industries that the bank funded. The short lived 
innovative programme (a flash of strategic brilliance) demonstrates the 
lost opportunity for long term skills and finance capability building. 
 Government interventions to assist companies to access 
investment capital 
 There is therefore a need for micro-level financial skills to be developed 
within the industry and within the financial community. However, it is 
also recognized that governments need to intervene to enable compa-
nies to access affordable investment capital. What types of interventions 
can governments employ to help resolve this critical issue? A govern-
ment can provide soft loans, or it can use direct intervention to reduce 
 Table 15.3  Recruitment of non-traditional banking skills to build finance capa-
bility by one Zimbabwean international bank in 1998–2000 
 Intake  Skills Sets  Roles in the Bank 
1 Engineers, Economists Credit Risk Analysis, Monitoring 
and Management; Relationship 
Management; Processing; Global 
Markets; Retail Banking
2 Engineers (electrical, 
mechanical and civil), 




Credit Risk Analysis, Monitoring 
and Management; Relationship 
Management; Processing; Marketing; 
Treasury (Global Markets); Retail 
Banking; Direct Banking; Branch 
Management; Credit Operations; 
Interest Recalculation; Structured 
Trade Finance; Transactional Banking; 
Syndicated Lending
3 Accountant, Scientist Credit Risk Analysis, Monitoring and 
Management; Finance; Treasury Back 
Office Operations
 Source : Compiled by author from fieldwork in Zimbabwe (2010–13) and experience. 
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the cost of financing (e.g. interest subsidies). As well as such specific 
initiatives, it can intervene to create a conducive industry context that 
makes investment in the sector attractive to various providers of capital, 
thereby reducing perception of risk and theoretically increasing the 
availability of and reducing the cost of capital. Finally, a government 
can employ time-limited incentives to support industry investment. 
 Direct capital provision 
 Many industry actors and a number of trade associations have called for 
their governments to set up designated funds for low-cost investment in 
the pharmaceutical sector. One example is in Ghana, where in 2014 the 
President announced that Cedis 50 million would be set aside from the 
Export Development and Agriculture Investment Fund (EDAIF) for soft 
loans to the pharmaceutical sector (with recent currency depreciation 
this is now equivalent to less than USD$20 million). The government of 
Nigeria proposed a Naira 200 billion (roughly USD$100 million) fund to 
support the sector, but this has yet to materialize. 
 These limited examples to date suggest that for most countries, direct 
capital provision may not be viable or of sufficient impact to enable the 
transformation of the industry. Where countries (such as Ghana) have 
more than a handful of manufacturers, it is unlikely that governments 
have resources to create a fund of sufficient magnitude to tackle the 
capital funding gap for a meaningful number of companies. Furthermore, 
a government making direct capital provision must be equipped to 
make informed decisions, to ensure these scarce public resources are not 
wasted through poor investment. Public funding of investment capital 
for the pharmaceutical sector therefore demands the development of 
financial capabilities of the type just outlined within governments as 
well as private institutions. 
 However, where limited resources can be brought to bear, there is the 
potential for leveraging these public funds to assist a number of compa-
nies to achieve an affordable cost of capital. For example the propor-
tion of individual investments that a fund supports could be limited 
to a certain percentage of capital required. A blended cost of capital 
combining public with commercial investment can be more afford-
able than pure commercial capital. Such leverage could be enhanced 
if governments consider taking a junior debt position, thereby perhaps 
reducing the risk coupon required by private sector investors. 
 Assuming that an investment fund can be regularly recapitalized, 
through a sustainable funding mechanism such as a levy on pharma-
ceutical imports for example, public resources could be allocated in 
tranches. In this way the capital requirements of an organization at one 
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particular time during a project lifecycle can be addressed without tying 
up resources required for total overall capital requirements, and there-
fore a greater number of companies can be supported simultaneously 
over a number of years. 
 Direct government expenditure to reduce the cost of financing 
 Governments can also facilitate access to affordable investment capital 
through subsidizing interest payments. Interest subsidies were made 
available to Indian pharmaceutical manufacturers to support their 
development. Using public resources to support the servicing of debt 
rather than providing the capital itself can be a more efficient use of 
public resources. However, limitations on the political acceptability of 
direct transfer of public funds to the private sector, given other pressing 
demands on public expenditure, may make such a model untenable for 
many countries. At the least, mechanisms are essential to control waste 
of resources and limit government financial liabilities. 
 Can criteria be established for companies to be eligible for such subsi-
dies? There is widespread anxiety about governments trying to ‘pick 
winners’, or rather failing to spot losers, thereby backing unsustainable 
manufacturers and losing scarce funds to unintended uses. All industrial 
policy interventions require the development of industrial skills and 
capabilities within government. 
 Another concern may be that an interest subsidy approach can rein-
force a debt-financing model, shifting the industry away from equity 
financing. Equity financing should form an element of the capital struc-
ture of firm in which the return on investment is necessarily long term. 
Hence, parallel mechanisms may be needed to encourage companies to 
seek some equity financing to cover some of the capital requirements 
for upgrading. These mechanisms could include facilitating repatriation 
of profits, to stimulate interest from foreign investors, or levelling the 
playing field between debt and equity financing through limiting the 
tax shields that debt conveys. 
 Interest subsidies provide an investment incentive, but have the 
advantage that they do not have a direct impact on revenues and oper-
ating profitability, unlike preferential pricing or other forms of market 
protection. They may therefore be a constructive means of support in 
that they do not encourage uncompetitive practices. 
 Creating an industry context that attracts capital 
 Creating a conducive context for pharmaceutical manufacturing 
involves the combination of multiple interventions, not all of which 
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are necessarily within the purview of individual governments. The 
importance of a regional market has already been highlighted. However, 
individual governments can tackle dimensions such as the overall busi-
ness environment (corporate tax rates and special economic zones, 
for example), as well as sector-specific aspects such as strengthening 
regulatory oversight and developing human resources. While credible 
forward-looking statements from governments help, genuine impact 
does require observable developments and interventions. 
 The role of time-limited incentives 
 The PMPA Business Plan, regional plans and national strategies all call 
for time-limited incentives. Given the specific nature of the pharma-
ceutical industry, what is the purpose of these incentives, what are 
the tools available to governments and how do these vary by country 
context? 
 First, there is a clear distinction to be made between time-limited 
incentives and policies to induce structural change whether on the 
demand or supply side. For instance, resolving the widespread unequal 
tax and duty regimes applied to imports versus inputs for local produc-
tion (Chapters 2–6) is a long-term structural approach that needs to be 
embedded. However, it is also possible to decide to adjust tax regimes for 
a limited period of time, to convey a temporary competitive advantage 
to local producers in competition with imports. 
 Examples of time-limited incentives that could be utilized can be 
drawn from the policy actions already implemented within Africa, on 
other continents, and for other industries. A major concern for manu-
facturers is funding their working capital requirements. For African 
companies this is a particularly profound problem, since they need to 
import the vast majority of inputs from abroad. Often, credit terms 
are used up before raw materials can even begin to be converted into 
final formulations. Such concerns can be addressed through provision 
of working capital credits, an approach that was used successfully in 
India, or through underwriting letters of credit enabling manufacturers 
to secure improved credit terms from their suppliers. 
 Other government incentives can focus on reducing the tax burden 
for which companies are liable, as a means to free up resources to 
fund investment. Effectively, this provides an additional margin that 
can make local products more competitive in the transition period, as 
companies learn to operate facilities more efficiently. Examples of incen-
tives to achieve these intents are tax holidays and special depreciation 
provisions. The latter were once again used in India where companies 
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were able to include depreciation over time on the profit and loss state-
ments up to 150% of the capital cost for plants and equipment. 
 Previous chapters have covered the use of procurement preferences 
and restricted lists and highlighted the potential for such approaches to 
give a boost to local manufacturers. There are acknowledged downsides 
associated with market protection, particularly if done at a national 
rather than a regional level, since it can, for example, reduce competi-
tion. Introducing preferential import tariffs on inputs for local produc-
tion is another mechanism to provide a degree of protection for nascent 
industries. Again, a regional approach that consolidates markets can 
help to implement this while sustaining local competition. 
 This discussion is far from exhaustive in covering the range of indus-
trial policy incentives available. The relative merits of the different tools 
depend strongly on context, but their fundamental purpose is to support 
the industry during a transition phase so that companies can build 
capabilities, develop plans for upgrading facilities and execute them, 
whilst continuing to compete viably during the transition. This transi-
tion period also provides time for policy makers to put in place longer 
term initiatives to sustain the economic and technical viability of high-
quality manufacturing, including defragmenting markets and building 
the institutional capacities and skills within government and industry 
actors. Initiatives are under way to address these structural realities, but 
a much stronger push is still required, with the support of international 
technical assistance programmes to build government skills and accel-
erate industrial knowledge accumulation. 
 The importance of country context 
 Each country considering development of its pharmaceutical industry 
faces a unique context which determines what policies and initiatives 
are required and feasible. With a large domestic market, a government 
could employ protective measures to support industry growth, using 
import substitution as Ethiopia has done (Chapter 4). For smaller coun-
tries, however, regional exports are likely to be a critical part of the busi-
ness mix for a sustainable industry. Botswana has an expressed desire to 
establish a pharmaceutical industry, but with a population of 2 million, 
its strategic positioning objective is to become a regional centre for phar-
maceutical production. 
 Another key variable is the state of the public finances. All countries 
face choices as to where they invest public resources, and where such 
resources are severely constrained, the Ministry of Finance and the 
National Revenue Authority are likely to resist policy initiatives that will 
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reduce the contribution of current taxes levied on the sector to govern-
ment income, or that increase expenditure through for example procure-
ment preferences or industry subsidies. For example, at present, Ghana 
and Kenya face difficult public finance situations, making budget-neutral 
support mechanism such as domestic market protection an attractive 
option. While the options open to governments and their relative power 
vary according to the specific context, complementary regional initia-
tives such as tariff harmonization, regulatory harmonization and general 
collaboration between countries can increase the leverage that national 
government interventions have to stimulate upgrading and develop-
ment of the sector. 
 Conclusion 
 We began by highlighting recent developments at regional, continental 
and international levels that have generated a new convergence of high-
level political will to support the development of the pharmaceutical 
manufacturing industry in Africa. The chapter has sought to shift the 
understanding of the key challenge of investment finance within those 
strategies, from a focus on access to capital to a framework of collabo-
rative financial capability building in firms, financial institutions and 
governments. The chapter outlines the shared political recognition of 
the need for time, protection and incentives to build the industrial base 
through upgrading and transition to higher skills and quality stand-
ards. Development of new skills within interconnected institutions, 
evolution of regional markets and firms making the requisite invest-
ments and learning to operate competitively at international standards 
cannot happen overnight. This final chapter, framed by the intensive 
international and regional collaborations that are now under way, also 
frames the detailed studies in this book as a timely contribution to those 
endeavours. 
 Note 
 1 .  See the World Trade Organisation website at  https://www.wto.org/english/
tratop_e/trips_e/trips_e.htm for more information on TRIPS. 
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